Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Forecasted to Earn Q1 2023 Earnings of ($1.16) Per Share

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) – Analysts at Lifesci Capital issued their Q1 2023 earnings per share estimates for shares of Tarsus Pharmaceuticals in a note issued to investors on Tuesday, March 14th. Lifesci Capital analyst P. Dolezal forecasts that the company will post earnings of ($1.16) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($4.82) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q2 2023 earnings at ($1.27) EPS, Q3 2023 earnings at ($1.86) EPS, Q4 2023 earnings at ($1.75) EPS and FY2023 earnings at ($5.96) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday.

Tarsus Pharmaceuticals Trading Down 5.0 %

Shares of TARS opened at $12.75 on Friday. The company has a market capitalization of $340.04 million, a PE ratio of -5.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.40 and a current ratio of 16.40. The stock has a fifty day moving average of $15.07 and a two-hundred day moving average of $15.88. Tarsus Pharmaceuticals has a fifty-two week low of $10.80 and a fifty-two week high of $19.66.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 9,000 shares of the company’s stock in a transaction on Wednesday, February 8th. The stock was sold at an average price of $15.14, for a total transaction of $136,260.00. Following the completion of the sale, the chief executive officer now directly owns 1,102,106 shares in the company, valued at approximately $16,685,884.84. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Bobak R. Azamian sold 8,000 shares of the stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $13.79, for a total value of $110,320.00. Following the completion of the sale, the chief executive officer now directly owns 1,080,536 shares in the company, valued at approximately $14,900,591.44. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Bobak R. Azamian sold 9,000 shares of the stock in a transaction on Wednesday, February 8th. The shares were sold at an average price of $15.14, for a total value of $136,260.00. Following the completion of the sale, the chief executive officer now owns 1,102,106 shares of the company’s stock, valued at $16,685,884.84. The disclosure for this sale can be found here. Insiders sold a total of 59,500 shares of company stock worth $867,578 in the last ninety days. Insiders own 33.08% of the company’s stock.

Institutional Trading of Tarsus Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. UBS Group AG increased its holdings in Tarsus Pharmaceuticals by 37.0% in the 1st quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after purchasing an additional 1,142 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 13.0% in the 4th quarter. JPMorgan Chase & Co. now owns 11,351 shares of the company’s stock valued at $167,000 after purchasing an additional 1,309 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Tarsus Pharmaceuticals by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after buying an additional 1,402 shares during the last quarter. State Street Corp boosted its position in Tarsus Pharmaceuticals by 2.4% in the 1st quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after buying an additional 3,141 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in Tarsus Pharmaceuticals by 33.8% in the 4th quarter. Bank of America Corp DE now owns 15,544 shares of the company’s stock valued at $228,000 after buying an additional 3,924 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.